Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan
16 févr. 2023 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based...
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference
22 nov. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
10 nov. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual...
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance
07 nov. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
20 oct. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting
17 oct. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
04 oct. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
21 sept. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
06 sept. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
15 août 2022 07h00 HE
|
Talaris Therapeutics, Inc.
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were...